Previous studies have demonstrated that CD69-deficient mice or those treated with anti-CD69 antibody therapy have reduced tumor growth rate and metastatic burden,35 however, our study clearly demonstrates that anti-CD69 treatment alone or in combination with PI-3065 did not result in tumor control (online supplemental figure 1A and B). The gene discussed is CD69; the disease is neoplasm.